Papers/PMID:35345991
The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Current pharmaceutical design2022The record
2 findings drawn from this paper, on 1 compound across 2 endpoints.
What it reported
How to read these marksWhat moved
2 findings
curcumin — decreases fasting blood glucose
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×1“The results showed that curcumin consumption can significantly reduce AST (-0.35, (-0.57 to -0.14)), total cholesterol (-0.81, (-1.34 to -0.27)), TG (-0.49, (-0.71 to -0.27)), and FBS (-0.28, (-0.46 to -0.09)) in patients with NAFLD.”
Quoted verbatim from The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- adults with NAFLD, meta-analysis of 14 RCTs
curcumin — decreases total cholesterol (TC)
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×2“The results showed that curcumin consumption can significantly reduce AST (-0.35, (-0.57 to -0.14)), total cholesterol (-0.81, (-1.34 to -0.27)), TG (-0.49, (-0.71 to -0.27)), and FBS (-0.28, (-0.46 to -0.09)) in patients with NAFLD.”
Quoted verbatim from The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- adults with NAFLD, meta-analysis of 14 RCTs